Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone diacetate
Drug ID BADD_D02273
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00984
MeSH ID C030262
PubChem ID 6216
TTD Drug ID Not Available
NDC Product Code 38779-0166; 46439-8766; 52128-171; 62991-2175; 49452-7910
Synonyms triamcinolone diacetate | Polcartolone | Polcortolon
Chemical Information
Molecular Formula C25H31FO8
CAS Registry Number 67-78-7
SMILES CC(=O)OCC(=O)C1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)OC(=O)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Acne23.02.01.001--Not Available
Alkalosis hypokalaemic14.01.02.002--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Arachnoiditis17.06.01.001; 12.02.04.002--
Arrhythmia02.03.02.001--Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blood potassium decreased13.11.01.010--Not Available
Bradycardia02.03.02.002--Not Available
Calcinosis08.03.04.002--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac arrest02.03.04.001--
Cardiomegaly02.04.02.001--Not Available
Cataract subcapsular06.06.01.002--Not Available
Circulatory collapse24.06.02.001--Not Available
Cushingoid24.08.02.004; 19.07.03.001; 14.11.01.006; 05.01.01.002--
Depression19.15.01.001--
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Erythema23.03.06.001--Not Available
Euphoric mood19.04.02.006--
Exophthalmos06.09.04.001; 05.02.02.002--Not Available
Fat embolism12.01.08.003; 24.01.01.012--Not Available
Fat tissue increased08.01.03.009--Not Available
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Gastrointestinal perforation07.04.04.001--Not Available
Glaucoma06.03.01.002--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages